Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,970 JPY
Change Today -3.00 / -0.15%
Volume 76.8K
As of 2:00 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

zeria pharmaceutical co ltd (4559) Snapshot

Open
¥1,980
Previous Close
¥1,973
Day High
¥1,980
Day Low
¥1,953
52 Week High
07/28/14 - ¥2,633
52 Week Low
01/23/15 - ¥1,876
Market Cap
104.6B
Average Volume 10 Days
208.6K
EPS TTM
¥74.46
Shares Outstanding
53.1M
EX-Date
03/27/15
P/E TM
26.5x
Dividend
¥30.00
Dividend Yield
1.52%
Current Stock Chart for ZERIA PHARMACEUTICAL CO LTD (4559)

Related News

No related news articles were found.

zeria pharmaceutical co ltd (4559) Related Businessweek News

No Related Businessweek News Found

zeria pharmaceutical co ltd (4559) Details

Zeria Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents. The company also provides cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, and analytical equipment. Its ethical pharmaceutical products include functional dyspepsia treatment products, histamine h2 receptor antagonists, zinc containing anti-ulcerants, oral bowel cleansing products, laxative products, ulcerative colitis remedies, and proton pump inhibitors in the gastrointestinal field. The company’s products also include hypophosphatemia treatment products, long-acting calcium channel blockers, absorbable topical hemostats, sclerotherapy products for leg varicose veins, enzymatic hemostatics, anti-platelet oral jellies, oral non-steroidal anti-inflammatory products, anti-leukopenia after radiotherapy products, topical non-steroidal anti-inflammatory products, anti-inflammatory topical blood circulation enhancers, and non-steroidal anti-inflammatory ophthalmic solutions. In addition, Zeria Pharmaceutical Co., Ltd. offers OTC drugs and products, such as self-prevention products, remedies for gastrointestinal diseases, dermal remedies/cosmeceuticals, ophthalmic solutions, cold remedies, nutrient tonics, and topical anti-inflammatory analgesics. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

1,322 Employees
Last Reported Date: 06/27/14
Founded in 1955

zeria pharmaceutical co ltd (4559) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeria pharmaceutical co ltd (4559) Key Developments

Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Year Ending March 31, 2015; Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2015

For the year ending March 31, 2015, Zeria Pharmaceutical Co., Ltd. provided year end dividend forecast of ¥15.00 per share compared to ¥15.00 per share declared last year. The company reported consolidated earnings results for the nine months ended December 31, 2014. For the nine months, the company reported net sales of ¥45,782 million, operating income was ¥3,340 million, ordinary income of ¥3,333 million and net income was ¥3,160 million or ¥59.50 per share compared to net sales of ¥46,773 million, operating income was ¥5,965 million, ordinary income of ¥6,068 million and net income was ¥4,571 million or ¥100.53 per share for the same period a year ago. The company provided earnings guidance for the fiscal year ending March 31, 2015. For the period, the company expected net sales of ¥64,000 million, operating income was ¥5,000 million, ordinary income of ¥5,000 million and net income was ¥4,300 million or ¥80.95 per share.

Zeria Pharmaceutical Co., Ltd. to Report Q3, 2015 Results on Feb 05, 2015

Zeria Pharmaceutical Co., Ltd. announced that they will report Q3, 2015 results on Feb 05, 2015

Zeria Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Six Months Ended Sep. 30, 2014; Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2015; Announces Dividend for the Six Months Ended Sep. 30, 2014, Payable on December 2, 2014; Provides Dividend Guidance for the Full Year Ending March 31, 2015

Zeria Pharmaceutical Co., Ltd. announced consolidated earnings results for the six months ended Sep. 30, 2014. For the period, the company reported net sales of ¥30,136 million, operating income was ¥2,279 million, ordinary income of ¥2,240 million and net income was ¥2,115 million or ¥39.83 per share compared to net sales of ¥30,109 million, operating income was ¥4,060 million, ordinary income of ¥4,223 million and net income was ¥3,336 million or ¥73.37 per share for the same period a year ago. The company provided consolidated earnings guidance for the full year ending March 31, 2015. For the full year, the company expects net sales of ¥64,000 million, operating income was ¥5,000 million, ordinary income of ¥5,000 million and net income was ¥4,300 million or ¥80.95 per share. The company announced dividend of ¥15.00 per share for the six months ended Sep. 30, 2014. Scheduled date to commencement of dividend payments is December 2, 2014. The company expects year-end dividend of ¥15.00 per share for the full year ending March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4559:JP ¥1,970.00 JPY -3.00

4559 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4559.
View Industry Companies
 

Industry Analysis

4559

Industry Average

Valuation 4559 Industry Range
Price/Earnings 26.5x
Price/Sales 1.7x
Price/Book 1.7x
Price/Cash Flow 27.2x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZERIA PHARMACEUTICAL CO LTD, please visit www.zeria.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.